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Abstract. Zanzibar has transitioned from malaria control to the pre-elimination phase, and the continued need for
intermittent preventive treatment during pregnancy (IPTp) has been questioned. We conducted a prospective observa-
tional study to estimate placental malaria positivity rate among women who did not receive IPTp with sulfadoxine-
pyrimethamine. A convenience sample of pregnant women was enrolled from six clinics on the day of delivery from
August of 2011 to September of 2012. Dried placental blood spot specimens were analyzed by polymerase chain reaction
(PCR); 9 of 1,349 specimens (0.7%; precision estimate = 0.2–1.1%) were PCR-positive for Plasmodium falciparum.
Placental infection was detected on both Pemba (N = 3) and Unguja (N = 6). Placental malaria positivity in Zanzibar was
low, even in the absence of IPTp. It may be reasonable for the Ministry of Health to consider discontinuing IPTp,
intensifying surveillance efforts, and promoting insecticide-treated nets and effective case management of malaria
in pregnancy.
INTRODUCTION
The devastating consequences of malaria in pregnancy
(MIP) on maternal and newborn health are well-documented.
Pregnant women in areas of both stable and unstable malaria
transmission are at increased risk for peripheral and placental
Plasmodium falciparum infection, with symptomatic infections
being more common in areas of unstable transmission.1–4 The
adverse maternal outcomes of MIP in both transmission set-
tings include severe anemia and mortality, with higher case
fatality rates in lower-transmission settings.3,5,6 In addition,
MIP is associated with low birth weight (LBW; < 2,500 g),7 an
important risk factors for infant mortality.2,8,9
In areas of stable malaria transmission, the World Health
Organization (WHO) promotes a three-pronged strategy to
prevent adverse consequences of MIP, including (1) intermit-
tent preventive treatment during pregnancy (IPTp) using
sulfadoxine-pyrimethamine (SP), (2) use of insecticide-treated
bed nets (ITNs), and (3) effective case management through
prompt detection and treatment of malaria and anemia in
pregnancy.10–12 Zanzibar adopted this three-pronged approach
in 2004 when malaria transmission was high and stable.13 Since
2006, Zanzibar has scaled up long-lasting insecticidal nets
(LLINs) and indoor residual spraying (IRS), improved case
detection with malaria rapid diagnostic tests (mRDTs), and
introduced artemisinin-based combination therapy (ACT). A
marked decline in malaria prevalence in Zanzibar over the past
decade (from 50% in 2003 to 0.5% in 2012 among children
under 5 years of age) has shifted Zanzibar to the malaria pre-
elimination phase.13,14 In response, Zanzibar is now revising its
MIP control strategy. One question is whether to continue
IPTp. This study aimed to estimate the rate of placental
malaria infection at delivery among Zanzibari pregnant women
who had not received IPTp to help determine whether IPTp is
still warranted in Zanzibar.
METHODS AND MATERIALS
Study area and sites. Zanzibar is comprised of two main
islands approximately 40 km from mainland Tanzania: Unguja
(2012 population = 896,721; 1,666 km2) and Pemba (2012 pop-
ulation = 406,848; 998 km2).15,16 This study was conducted at a
purposive sample of 6 of 38 health facilities in Zanzibar where
routine deliveries occur (3 facilities in Unguja [Mnazi Mmoja
Hospital, Mwembeladu Hospital, and Kivunge Health Center]
and 3 facilities in Pemba [Chake Chake Hospital, Wete Hospi-
tal, and Micheweni Health Center]) from August of 2011 to
September of 2012. These facilities were engaged in an ongoing
program supported by the US Agency for International Devel-
opment (USAID) designed to improve maternal and newborn
health services. Although these six hospitals covered approxi-
mately 82% of hospital deliveries on both islands, 50% of
women in Zanzibar deliver at home.17 The peak rainfall period
occurs from March to June, and the peak malaria transmission
period is from April to July.18
Eligibility and enrollment. Residents of Unguja or Pemba
delivering at a study facility were considered eligible if their
antenatal care (ANC) card indicated they had received no
doses of IPTp SP. Women were enrolled 24 hours/day every
day of the week by the clinic staff. Consecutive sampling was
used to enroll all eligible women during the 12-month study
period. However, because of the added burden on the clinic
staff, no listing was maintained of women who were eligible
but not enrolled. The 12-month enrollment ensured that both
low- and high-transmission seasons were represented.
Procedures. Women who delivered at the six facilities were
screened by examining their ANC card, which contains a
designated space for recording doses of IPTp SP received.
No additional questions were asked, because eligible clients
were typically in active labor. Eligible women who agreed
to participate were read an informed consent statement by
trained maternity nurses or nurse midwives, and their verbal
consent was obtained and recorded. No additional assent
options were offered to minors. A brief form, including age
of mother, gravidity, hemoglobin or hematocrit and week
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of gestation at which the measurement was taken, whether it
was a singleton or multiple birth, outcome of the birth, and
birth weight of the baby, was filled out by the health worker
with information extracted from each consenting mother’s
ANC card. The form was placed into the client’s file and
transferred to the delivery room with the client.
Collection of placental samples. After management of the
birth, a trained maternity nurse or nurse midwife at each
facility obtained a placental dried blood spot (DBS) speci-
men from the maternal side of the placenta. A single deep
incision was made, and five drops of blood were drawn up
with a pipette and dotted onto Whatman 903 Protein Saver
Card filter paper labeled only with the woman’s study identi-
fication (ID) number.19,20 DBS specimens were labeled,
packed with desiccant, and transferred to the University of
California, San Francisco for polymerase chain reaction
(PCR) to detect infection with Plasmodium (all species).
Although exact timing was not monitored, collection of each
specimen generally occurred within 30 minutes of delivery.
After collection of the specimen, the placenta was disposed
of per the facility’s routine procedures. Multiple births were
noted on the client’s study form. In the case of twins with one
placenta, one ID was issued. In the case of twins with two
placentas, each placenta was assigned a unique ID number
and tested. Corresponding placental ID numbers were noted
on the client form.
Laboratory analysis. DNA from each DBS was extracted
using the QIAampDNAMicrokit following the manufacturer’s
instructions (Qiagen, Germantown, MD). Plasmodium DNA
was amplified by 18S ribosomal DNA PCR, with the species-
specific nested round confirming falciparum species.21 The
presence of PCR product was evaluated using agarose gel elec-
trophoresis stained with ethidium bromide. Testing of control
samples extracted from DBSs with known parasite densities
confirmed a limit of detection of < 10 parasite/mL.
Sample size. The required sample size was calculated to be
1,825 assuming a parasitemia prevalence of 5% with a 95%
confidence interval with precision of ±1% point. The sample
size was calculated assuming independence of observations,
because intracluster correlations could not be assessed, but
the expected prevalence was liberally estimated to help
account for unknown variables. Initial results indicated prev-
alence well under the liberal prevalence estimate used in the
sample size assumptions, indicating that fewer samples were
needed to attain the necessary power for the study, but data
collection continued to allow for coverage throughout both
the rainy and dry seasons.
Data processing and analysis. Client forms were entered
into an Access database and date stamped, and hard copies
were filed chronologically along with the consent forms. Data
on PCR status were provided in an Excel spreadsheet, and the
ID numbers were matched between the two files. Cleaned data
were exported into SPSS, version 20 and Stata, version 11 for
analysis. Although we attempted to enroll all eligible women,
given the total number of deliveries and the expected propor-
tion of women who did not receive IPTp (25%),14 it is likely
that some of the eligible women were not enrolled. Given that
the participants in this study were a non-probability sample of
all eligible women, the 95% confidence interval given for the
proportion of women with placental parasitemia who did not
receive IPTp is considered a precision interval rather than a
confidence interval.
Ethics/institutional review. Ethical approval was provided
by the Zanzibar Research Council, Johns Hopkins School
of Public Health Institutional Review Board, and the US
Centers for Disease Control and Prevention, Atlanta.
RESULTS
Patient characteristics. In total, 1,411 pregnant women
were enrolled at the time of delivery. Data and specimens
from 74 enrollees were not analyzed because of mislabeling,
duplicate IDs, missing client cards, or loss. After exclusion of
these 74 women, our analysis included 1,339 women from
Pemba (N = 694) and Unguja (N = 645). The average age of
enrolled women was 27 years (range = 15–48 years), and 433
(32%) women were primigravidae (Table 1). The proportion
of primigravidae varied by facility (from 14% of the enrolled
women at Mwembeladu to 42% of the enrolled women
at Mnazi Mmoja). The enrollees included both singleton
(N = 1,326) and twin (N = 13) pregnancies. Birth outcomes
experienced by these women included 1,308 (97%) live
births, 22 (2%) stillbirths, and 73 (5%) LBW deliveries
(Table 1). The majority of enrolments (67%) occurred in
the first 4 months of the study (Figure 1), likely because of
SP stockouts preceding and during this period. Overall, 6%
of all deliveries at the six facilities were enrolled (ranging
from 4% to 15%). Although only 23% of all deliveries at
Zanzibar health facilities occurred on Pemba in 2011, deliv-
eries from Pemba comprised 52% of the total enrolment
in this study.
Characteristics of placental parasitemia cases. In total,
1,349 placental specimens were processed and analyzed for
presence of malaria infection by PCR (Table 2). Nine (0.7%;
precision estimate = 0.2–1.1%) were positive for P. falciparum,
with no other Plasmodium species detected.
Placental infection was detected during 6 of 12 months of
enrolment, with no seasonal variation. Unguja and Pemba
accounted for six (66%) and three (33%) of the positive pla-
cental specimens, respectively (Figure 2). Detection of cases
in the low-transmission season (September to December) was
likely the result of increased study enrolment eligibility
during these months as a result of SP stockouts (Figure 1).
Seven (78%) positives originated from two of six enrolment
facilities: Mwembeladu Hospital and Micheweni Health
Center on Unguja and Pemba, respectively. In Pemba, pla-
cental infection (N = 3) was only detected at Micheweni, but
at least one placental infection was detected at each of three
Unguja facilities.
Birth outcomes among nine placental infections included
one stillborn infant of LBW (< 2.5 kg). None of the remaining
women with placental parasitemia delivered an LBW infant.
Three women with placental parasitemia had hemoglobin tests;
two women were anemic (hemoglobin < 11 g/dL) (Table 3).
The proportion of anemic women at time of delivery was
similar in women with and without placental malaria. Three
positive specimens came from primigravidae women, propor-
tionate to the percent of primigravidae sampled in the study.
DISCUSSION
The prevalence of placental malaria at the time of delivery
in Zanzibar was very low among women in this study who did
not receive IPTp SP, with an infection rate of 0.7% (precision
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estimate = 0.2–1.1%) by PCR. Data from screening women
for peripheral parasitemia at first ANC visit with mRDTs at
government health facilities shows a similar low prevalence of
0.2% among 19,724 women in 2011 and 27,186 women in
2012,22,23 confirming the low risk of MIP in Zanzibar. These
data triangulate well with Zanzibar’s Malaria Early Epidemic
Detection System (MEEDS), which collects weekly data from
all government facility outpatient departments. MEEDS
reported a malaria positivity rate of 1.2% and 0.9% among
all febrile or otherwise symptomatic outpatients tested during
2011 and 2012, respectively (Zanzibar Malaria Control Pro-
gram, unpublished data).
The low prevalence of malaria overall and particularly, the
low prevalence documented in pregnant women who deliver
in health facilities raises multiple questions about the use of
continuing IPTp SP as part of ANC services in Zanzibar. In
areas of moderate to high malaria transmission, the WHO
recommends IPTp in addition to ITNs and effective case
management. In African countries that have substantially
reduced malaria transmission after successful scale up of mul-
tiple control efforts, the WHO continues to recommend pro-
vision of IPTp.12,24 Despite this recommendation, Rwanda
discontinued their national IPTp program in 2008 because of
increased prevalence of SP resistance combined with declin-
ing malaria prevalence.25 The WHO’s Malaria Policy Advi-
sory Committee recently considered an Evidence Review
Group (ERG) recommendation to discontinue IPTp SP when
malaria transmission has been very low (falciparum malaria
population prevalence in children under 15 years of age below
5%) for at least 3 years. The ERG’s recommendation was
based on findings from two unpublished analyses that sug-
gested that, as transmission falls to very low levels, the fraction
of malaria-attributable LBW prevented by IPTp SP continues
to decline.26 The ERG emphasized that discontinuation of
IPTp would require simultaneous maintenance and strengthen-
ing of vector control, prompt diagnosis and effective treatment,
and surveillance systems to monitor malaria transmission. As
of late 2013, the WHO had not changed its recommendation
against discontinuation of IPTp, because the threshold value
where IPTp SP confers no benefit remains undefined.
The potential for malaria resurgence in Zanzibar remains,
given historical observations, population movement, and
proximity to mainland Tanzania.27 It is reassuring that, since
2007, the population prevalence of malaria in cross-sectional
household surveys in Zanzibar has remained below 1% and
that, since 2008, MEEDS data indicate positivity rates well
below 5% among febrile outpatients. Tanzania mainland has
also reduced malaria prevalence among children 6–59 months
of age (from 18% in 2007 to 10% in 2012).14 However, trans-
mission in the nearby coastal regions Pwani and Tanga (10%
and 6% prevalence, respectively, in 2012) remains substan-
tially higher than in Zanzibar. Zanzibar’s proximity to the
mainland must be taken into consideration in any discussion
to discontinue IPTp, particularly considering complexities
and costs associated with restarting the IPTp SP program
after discontinuation in case that is warranted.
The seasonal increases in malaria transmission and focal
hot spots in Zanzibar must also be considered. After the rainy
season each year, confirmed cases of malaria rise during May
to July. Weekly malaria positivity rate has exceeded 5%
Table 1













Mnazi Mmoja 10,338 375 27 (15–46) 160 (42) 5 (1)
Mwembeladu 5,665 205 28 (17–46) 29 (14) 2 (1)
Kivunge 1,420 65 25 (16–42) 25 (37) 2 (3)
Pemba
Chake Chake 2,838 415 27 (15–48) 132 (32) 3 (1)
Wete 1,607 189 27 (16–48) 50 (26) 1 (1)
Micheweni 645 90 25 (17–42) 37 (41) 0 (0)
Total 22,563 1,339 27 (15–48) 433 (32) 13 (1)
*These figures represent deliveries during the 2011 calendar year.
Figure 1. Placental specimens collected by month in Pemba and Unguja, Zanzibar.
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(threshold for pre-elimination) one time per year in both 2010
and 2012 (maximum weekly positivity of 10% among patients
³ 5 years of age).28 Thus, although the overall annual malaria
prevalence and outpatient positivity rates remain extraordi-
narily low, periodic localized increases in malaria transmis-
sion do occur. As a strategy for prevention of MIP, however,
it is unlikely that administering SP to all Zanzibari pregnant
women throughout the year would significantly modulate risk
during these brief periods of increased malaria transmission.
Because of Zanzibar’s proximity to the mainland,
approaches to control of MIP must include a strong compo-
nent of surveillance and maintenance of high ITN use as well
as ensure access to prompt diagnosis and effective treatment.
The MEEDS surveillance system does not adequately moni-
tor MIP for two reasons: (1) the entry point to MEEDS is
limited to outpatient departments (OPDs), whereas symp-
tomatic ANC clients may report to ANC clinics, and (2) the
system does not capture pregnancy status of adults who pres-
ent to OPDs. Enhanced surveillance of MIP could be
achieved through inclusion of ANC malaria test results into
MEEDS and modification of MEEDS to allow reporting of
outpatient test results stratified by pregnancy status.
Among the alternatives to IPTp SP are two screening and
treatment approaches: (1) intermittent screening and treat-
ment of MIP (ISTp), in which every woman is tested at every
ANC visit, and (2) single screen and treatment (SSTp), in
which all pregnant women are tested at the first ANC visit
and only symptomatic women are screened thereafter. Data
comparing ISTp with IPTp from a single trial in Ghana
show similar reductions in maternal morbidity, peripheral
parasitemia, and LBW with ISTp (using SP or amodiaquine-
artesunate) compared with IPTp SP.29 Additional studies
comparing the effectiveness of IPTp SP with ISTp with
artemether-lumefantrine are underway in East Africa, and
results are expected in 2015 (ClinicalTrials.gov Identifier
NCT01084213). SSTp is currently the national policy in
Indonesia, where an ongoing study is comparing SSTp and
ISTp using dihydroartemisinin-piperaquine for treatment.
However, these data are not available to address the current
decision-making process for a revised MIP strategy in
Zanzibar. Another complication is that neither ISTp nor SSTp
is currently endorsed by the WHO.
Both IPTp and widespread screening in ANC have cost
implications, including commodity, logistics, training, supervi-
sion, and monitoring costs. Screen and treat strategies are
likely to be more costly than IPTp SP given the higher cost of
the RDTs compared with SP. In a setting with virtually no
cases of malaria, these costs must be weighed against the
potential risks and benefits to mothers and newborns, includ-
ing the potential for serious adverse drug reactions related to
SP use (estimated at 11.6–25.0 events per 100,000 exposures
with a mean cost per episode of US$24.15 [range = US$0–
226.04]).30 Given the cost implications of screen and treat
programs, a setting such as Zanzibar, with a prevalence per-
sistently below 1%, may reasonably consider discontinuing
IPTp SP without implementing a screen and treat program.
Such a move would necessitate maintaining and improving
the other pillars of malaria prevention, including use of ITNs,
effective case management, and additional enhancement of
the existing surveillance system.
ITNs remain a critical part of the overall malaria control
strategy supported by the Roll Back Malaria Partnership.
ITNs not only provide protection to pregnant women but also
reduce all-cause mortality among infants and young children
by up to 20%.31 High ITN use at the community level has also
achieved malaria transmission reductions.32 Provision of ITNs
to pregnant women is one avenue to maintain continuous high
coverage. Furthermore, in a large randomized controlled trial
in a low-transmission setting in Uganda, ITNs and IPTp pro-
vided equivalent benefit to pregnant women.33 This finding
suggests that, where ITN distribution forms part of the basis
for general malaria control, it may be reasonable to discon-
tinue IPTp and continue high ITN coverage as one strategy to
avert MIP.
Limitations. This study is limited to the cross-sectional
prevalence of placental parasitemia among a consecutive
sample of women delivering in health facilities in Zanzibar,
but more than one-half of the women in Zanzibar deliver at
home. The representativeness of our study sample may be
questioned, because it is not unreasonable to presume that
women delivering at home are less likely to receive IPTp and
thus, more likely to be at risk for malaria infection. However,
the high level of concordance among the results of our study,
MEEDS, and findings from ANC screening provides reassur-
ance that these results are valid. Receipt or non-receipt of
IPTp SP was determined solely by reviewing the client ANC
card at delivery, which means that the quality of information
for enrolment eligibility was limited by the recording prac-
tices of ANC providers. In most cases where women had not
received IPTp SP, it was indicated rather than just an absence
of a marking on the card. Because SP is not widely available
outside of ANC (in 2011, the Zanzibar Food and Drug Board
banned the sale of SP and artemisinin monotherapies from
private drug shops), the proportion of women who could have
received SP outside of ANC (and thus, been misclassified as
not receiving SP) is negligible. National survey data confirm
that the proportion of women reporting receipt of any anti-
malarial in pregnancy (85%) is virtually identical to the pro-
portion reporting having received SP from the ANC (84%).14
Because of SP stockouts, most women were enrolled in low-
transmission months (September to December), potentially
resulting in lower prevalence of placental malaria. Although
we attempted consecutive enrollment of all eligible women,
it is likely that it did not occur. Because no record was
Table 2
Distribution of malaria-positive placental specimens (N = 9) among
study participants in 2011–2012
Characteristic Positive, n (%) Total, n P value
Season 0.63
September to December 6 (1) 1,014
January to April 2 (1) 143
May to August 1 (1) 192
Facility 0.004
Unguja
Mnazi Mmoja 1 (< 1) 380
Mwembeladu 4 (2) 207
Kivunge 1 (1) 67
Pemba
Chake Chake 0 (0) 416
Wete 0 (0) 189
Micheweni 3 (3) 90
Gravidity 1.0
Primigravidae 3 (1) 433
Multigravidae 6 (1) 916
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maintained of women who were not enrolled, to minimize the
study-associated workload among busy labor/delivery ward
staff, the exact number of eligible women remains uncertain.
However, failure to enroll eligible women was likely related
to the workload at the time that the woman presented, which
is unlikely to be related to the outcome of interest. This limi-
tation did not likely compromise the generalizability of our
results to all pregnant women who did not receive IPTp deliv-
ering at these facilities. Because the facilities were selected
purposively from the facilities supported by a USAID-funded
program designed to improve maternal and newborn health
services, the generalizability of the findings to all pregnant
women who deliver at health facilities in Zanzibar cannot be
assured. The use of histopathology, rather than PCR alone,
would have allowed us a better estimation of the prevalence
of malaria throughout a longer proportion of the pregnancy;
however, it was beyond the scope of this study. Finally,
because this study did not enroll women who did receive IPTp
SP, no information was collected on the current protective
efficacy of IPTp SP in Zanzibar.
Conclusion. As malaria transmission in Zanzibar reaches
the pre-elimination phase, MIP policy and strategies must be
suitably adjusted. This study found a negligible level of
malaria among women who had not received IPTp SP. Given
the extremely low levels of malaria in both the general popu-
lation and pregnant women, discontinuing IPTp SP is one
Figure 2. Placental malaria infection cases in Pemba and Unguja, Zanzibar.
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reasonable option for Zanzibar to consider. A shift away from
IPTp SP as part of Zanzibar’s MIP control strategy should
only be considered if increased commitment is made to ensure
uninterrupted, high-quality access to malaria diagnosis and
treatment during pregnancy combined with enhanced mea-
sures to drive current transmission levels down closer to zero.
We further recommend enhanced surveillance of MIP
through reinforcement of the existing surveillance system to
ensure that cases among pregnant women are reported from
both ANC and outpatient settings in a timely manner. Efforts
should continue to ensure high ownership and use of ITNs,
particularly among women of reproductive age. Findings from
ongoing studies in higher-transmission areas on the cost effec-
tiveness of integrating screen and treat programs into ANC
services may not be directly relevant in Zanzibar, where prev-
alence of malaria is much lower. The Zanzibar Ministry of
Health should consider an internal review of costs and find-
ings from surveillance to inform on whether the cost of
screening every pregnant woman in ANC is a sound public
health investment.
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